Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Single-Arm, Phase Ib/II Clinical Study of Almonertinib Combined With Palbociclib in the Treatment of Patients With KRAS Mutations-Positive Advanced Solid Tumors

NCT06947811 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06947811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06947811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Single-Arm, Phase Ib/II Clinical Study of Almonertinib Combined With Palbociclib in the Treatment of Patients With KRAS Mutations-Positive Advanced Solid Tumors
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 9, 2025
Completion date
March 31, 2027
Enrollment
71 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr tyrosine kinase inhibitors plus cyclin-dependent kinase 4/6 inhibitor